#4 overall and #2 on NASDAQ. Can't complain at all. Now you sorta wonder how long until those analysts who missed their marks will take before raising their price estimates.
Growth looked very good. And especially compared to the others in the similar space who are doing very poorly. Very good for acquisition prospects down the road, I should htink.
So if I caught it right on the call, sounded like FDA has to respond pretty soon to the TICL.
And then there was another FDA channel so far as the Nanoflex, that they have to respond to within a few months?
I am quite looking forward to the cutover to US mfg, since they seemed to say expected tax rates would drop from 40% to 10%. That would be a nice earnings bump.
Anyway, so far as today, I've no complaints :)